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Phosphatidylinositol-3-kinase (PI3K) is a well-known regulator of cell division, motility, 
metabolism and survival in most cell types. Proper liver function and development highly depend 
on intact PI3K signal transduction. Aberrant PI3K pathway signaling in the liver is associated 
with hepatocellular carcinoma (HCC). In addition, PI3K signaling is involved in the homeostasis 
of lipid and glucose metabolism. Activation of the PI3K pathway induces lipogenesis and 
glycogenesis in the liver, since both Akt overexpressing transgenic mice and PTEN knockout 
mice develop fatty liver and hypoglycemia.  
Our laboratory characterized a novel protein that we call PI3K Interacting Protein 1 
(PIK3IP1) which binds to the p110 catalytic subunit of PI3K and reduces its activity in vitro.  
Little is known about PIK3IP1’s role in tumorigenesis and metabolism in vivo. Therefore we 
constructed PIK3IP1 transgenic mice (TG) which overexpress PIK3IP1 in hepatocytes under an 
albumin promoter in the C3H mouse strain to investigate the effect of PIK3IP1 on hepatocyte 
growth and metabolism, as well as HCC tumorigenesis. 
We detected a high expression level of PIK3IP1 in the livers from TG animals. The PI3K 
pathway was successfully suppressed both in liver tissues and isolated hepatocytes, which was 
confirmed by Western blots and phospho-protein array studies.  
Given the fact that PI3K signaling is associated with liver tumorigenesis, our next 
objective was to determine whether PIK3IP1 inhibits HCC development through PIK3IP1-
mediated downregulation of the PI3K pathway. In vivo, spontaneous liver tumorigenesis was 
significantly dampened in the transgenic animals. This was accompanied by decreased hepatic 
PI3K activity and reduced hepatocyte proliferation in the transgenics as compared to controls. 
Isolated PIK3IP1 transgenic mouse hepatocytes showed blunted PI3K signaling, DNA synthetic 
activity, motility and survival as compared to controls. 
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We then investigated the effect of PIK3IP1 on the maintenance of whole-body glucose 
and fat homeostasis. We observed that mice overexpressing PIK3IP1 have increased body 
weight, hyperglycemia, as well as increased visceral fat deposition. This suggests PIK3IP1 is an 
important regulator of metabolism. 
In conclusion, we successfully generated a transgenic mouse model with PIK3IP1 
overexpression in hepatocytes to assess the biological functions of PIK3IP1, an important 
negative regulator of PI3K, in liver tumorigenesis and insulin signaling. A high level expression 
of PIK3IP1 suppressed PI3K signaling pathway in vivo and in vitro, which curbs hepatic 
tumorigenesis. Furthermore, we show that PIK3IP1 overexpression can contribute to glucose 
homeostasis and fatty deposition. 
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1.0  INTRODUCTION 
The class IA phosphoinositol-3-kinases (PI3Ks) regulate important cellular processes 
such as proliferation, growth, survival, motility and metabolism. PI3K is stimulated by 
association of the p85 regulatory subunit with tyrosine phosphorylated proteins at the plasma 
membrane which leads to activation of the p110 catalytic subunit and generation of the second 
messenger phosphatidylinositol-3,4,5-trisphosphate [PI(3,4,5)P3] from phosphatidylinositol-4,5-
bisphosphate [PI(4,5)P2]. The appearance of PI(3,4,5)P3 attracts Akt (also known as Protein 
Kinase B [PKB]) and other signal transduction molecules to the membrane, the association of 
which triggers typical PI3K dependent cellular responses (Engelman, et al., 2006).   
 
Growth factor→Receptor tyrosine kinase→PI3K (GF→RTK→PI3K) pathways control 
cell proliferation, differentiation and apoptosis and are key regulators of liver development, 
tumorigenesis, regeneration and metabolism. For example, among the growth factors studied, 
HGF is now recognized as one of the most critical to maintaining proper liver homeostasis. It can 
also be considered a multifunctional cytokine with effects on many tissues and organs besides 
liver.  HGF and Met, the HGF receptor, are essential for hepatocyte DNA replication and mitosis 
during liver regeneration, and deletion of the HGF or Met genes during development causes an 
embryonic lethal phenotype (Schmidt et al., 1995). Additionally, HGF overexpression 
accelerates DEN-induced hepatocarcinogenesis (Horiguchi, et al., 2002) and ameliorates high-fat 
diet-induced fatty liver (Kosone et al., 2007).  
 
1.1 PIK3IP1:  A NOVEL NEGATIVE REGULATOR OF PI3K 
PIK3IP1 (mRNA ID: NM_052880; protein ID: NP_443112) was first identified as a 
novel kringle containing transmembrane protein in our laboratory (Zhu et al., 2007). The human 
PIK3IP1 gene structure contains 6 exons and 5 introns spanning about 12,000 bp, and it is 
located on human chromosome 22q12.2. In addition, we identified its ortholog in several species 
such as mouse (chromosome 11A1; GenBank I.D.:NP_835362), rat (chromosome 14q1; 
GenBank I.D.:XP_223593), chicken (GenBank I.D.: XP_415257) and zebrafish (chromosome 5; 
GenBank I.D.: CAM14081). They are highly homologous at the mRNA and protein levels.  
Human p85 beta shares homology with PIK3IP1 (Figure 1). Overall similarity is 70% and 
65% between PIK3IP1 (AA 197–219) and p85 beta (AA 502–524) or alpha (AA 505–527), 
respectively. An amino acid stretch (AA 210–218: NH2-EREMQRITL-COOH) within the p85-
like domain of PIK3IP1 is 78% identical to p85 beta (AA 515–523). 
 
 
Figure 1: Amino acid comparison of human PIK3IP1’s p85-like domain to the homologous 
region of human p85 beta.  
Alignment of the homologous regions of hPIK3IP1 and hp85 beta is shown. Solid lines indicate identical AA; dotted 
lines indicate similar AA. 
 
Functional assays show that PIK3IP1 binds to the p110 subunit of PI3K, and the 
interaction between PIK3IP1 and p110 leads to downregulation of PI3K activity (Zhu et al., 
2007). Interestingly, PIK3IP1 overexpressing cells also show enhanced sensitivity to 
staurosporine induced apoptosis.  
Altogether, our published data confirm that PIK3IP1 is the only adaptor protein identified 
so far that can directly bind to p110 and suppresses its activity. Furthermore, PIK3IP1 can also 
suppress pMEK1/2, pERK(p44/42), pp38MAPK and pSAPK/JNK, probably through inhibiting 
the PI3K pathway. 
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1.2 PI3K:  ROLES IN THE LIVER 
Class IA PI3K is activated by associating with RTKs by binding through one or two SH2 
domains in the regulatory PI3K subunit to phosphotyrosine consensus motifs in receptors and 
adaptor molecules. This leads to allosteric activation of the catalytic subunit to generate the 
second messenger phosphatidylinositol-3,4,5-trisphosphate (PI-3,4,5-P3) from the substrate 
phosphatidylinositol-4,5-bisphosphate (PI-4,5-P2). PIP3 recruits a subset of signaling proteins 
with pleckstrin homology (PH) domains to the membrane, including PDK1 and Akt. (Figures 2 
and 3) (Hunter, 2000; Fruman, et al., 1998; Fresno Vara et al., 2004).    
        
 
Figure 2: Class Ia PI3K signal cascades activated by RTKs 
 
 
 
 
PI3K directly binds to phosphotyrosine consensus residues of growth factor receptors or adaptors and the p110 
catalytic subunit of PI3K gets activated through allosteric activation. This will produce phosphatidylinositol-3,4,5-
trisphosphate (PIP3), an important second messenger. PIP3 recruits a subset of signalling proteins with PH 
domains to the membrane, including PDK1 and Akt. The activation of Akt by PDK1 will mediate the activation and 
inhibition of several targets resulting in survival, growth and proliferation through various mechanisms. PTEN, a 
PI-3,4,5-P3 phosphatase, negatively regulates the PI3K/Akt pathway by dephosphorylation of PIP3. (HFresno 
Vara JAH , et al., 2004) 
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In general, cell growth and survival are controlled by PI3K and other cellular kinases 
(e.g.,MAPK) in response to growth factors. Furthermore, activating PI3K/Akt dependent 
antiapoptotic pathways protects cells from apoptosis (Xiao et al., 2001; Franke et al., 2003; 
Kozman et al., 2002). 
Although the effects of HGF on liver regeneration, development and tumorigenesis have 
been extensively studied, the role of PI3K activity and function with regards to hepatocyte 
proliferation and apoptosis has not yet been completely clarified (Cho et al., 2003). Published 
studies suggest an important role for the PI3K pathway in hepatocyte metabolism, growth, 
survival and tumorigenic transformation.  For example, hypoxic preconditioning can reduce 
hepatocyte killing by hypoxia by about 35% (Carini et al., 2001). Hypoxic preconditioning 
stimulated phosphatidylinositol-3,4,5-triphosphate production and the phosphorylation of Akt, 
suggesting that PI3K can play a protective role in the development of hepatic tolerance to 
hypoxia/reperfusion (Carini et al., 2004). Interestingly, both p110 and p85 gene knock-out mice 
showed prenatal lethality (Bi L et al., 1999; Bi L et al., 2002; Fruman et al., 2000), and 
hepatocyte necrosis was reported in p85 knock-out mice (Bi et al., 1999). 
 
Figure 3: Scheme displaying the involvement of PI3K in the control of intracellular 
signaling pathways. 
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PI3K is activated via interaction with growth factor receptors (such as insulin receptor/IRS) or non-receptor (Src) 
tyrosine kinases. The main downstream effectors of PI3K are: Akt/PKB (responsible for anti-apoptotic signal 
transduction), Ras/Raf/ERK (the main mitogen-induced signal transduction pathway), and Rac/JNKK/JNK 
(partially controls the mitogen signal transduction but is involved mainly in other cell functions such as motility)  
 
1.3 RAS AND MAPK:  ROLES IN LIVER DEVELOPMENT AND REGENERATION  
The Ras-MAPK pathway is one of the most important cell signaling families in 
controlling liver function. Activation of p21Ras allows the recruitment and 
phosphorylation/activation of the cytosolic protein Raf (Marshall 1995; Madhani 2001; Plyte et 
al., 2000). Activation of Raf initiates sequential phosphorylation of MEK and ERK (MAPK) 
cascades (Seger et al., 1995). In spite of the fact that Ras induces MAPK, Ras can also activate 
PI3K and vice versa (Rodriguez-Viciana et al., 1994; Downward J 1998). These kinases have 
been demonstrated to play essential roles in cell growth, transformation differentiation and 
apoptosis.  
Ras increases DNA synthesis through C/EBP during partial hepatectomy (Ludde et al., 
2001). During liver development, K-Ras specifically mediates cytokine signaling for formation 
of the E-cadherin-based adherens junction, since fetal hepatocytes derived from K-Ras knockout 
(K-Ras-/-) mice failed to form adherens junctions in response to Oncostatin M (OSM), whereas 
adherens junction formation was induced normally by OSM in mutant hepatocytes lacking both 
H-Ras and N-Ras (Matsui et al., 2002). 
Inhibition of p42/44 MAPK does not significantly alter proliferation of hepatocytes 
isolated from regenerating liver, although inhibition of p38 MAPK results in decreased DNA 
synthesis in the same cells (Spector et al., 1997). Prominent, sustained ERK activation was seen 
in the liver during early postimplantation mouse development (5-10.5 days postcoitum) 
suggesting that the Erk-MAPK cascade participates in liver development (Corson et al., ) 
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2.0  POST-TRANSLATIONAL MODIFICATION OF PIK3IP1 
2.1 INTRODUCTION 
We identified and characterized a novel negative regulator of Class Ia 
phosphatidylinositol-3-kinases (PI3Ks) that we named phosphatidylinositol-3-kinase interacting 
protein 1 (PIK3IP1) (Zhu et al., 2007).  Our initial intention was to identify new kringle 
containing proteins by mining GenBank databases using the kringle signature amino acid 
sequence (NYCRNPD) and the cDNA of a well known kringle containing protein, HGF. 
Kringles are three disulfide-linked triple-looped motifs found in proteins with various functions 
such as coagulation, fibrinolysis, cell growth, and organogenesis. They mediate protein-protein 
interactions. Our search led us to the discovery of human and mouse expressed sequence tags 
(Ests) encoding for a putative transmembrane protein of about 263 amino acids bearing a signal 
peptide, a kringle domain extracellularly and a region intracellularly with homology to the p85 
regulatory subunit of PI3K (Figure 4).   
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Figure 4: Schematic of human PIK3IP1 cDNA and amino acid sequences.  
Green box–signal peptide; grey box–kringle domain; yellow box–transmembrane domain; aqua box–p85-like 
domain; pink stealth arrow–putative N-glycosylation site; black solid arrow–putative O-glycosylation site; green 
open arrow–last amino acid encoded by exon 5.  
 
 
 
We conducted several in vitro and in vivo functional assays which revealed that PIK3IP1 
binds to and negatively regulates the p110 catalytic subunit of PI3K. PI3Ks are key transducers 
of intracellular signals from tyrosine phosphorylated proteins such as growth factor receptors and 
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adapter proteins ultimately leading to cellular responses like changes in gene expression and 
modifications to metabolic pathways.  PI3Ks do so by converting the phospholipid PI(4,5)P2 to 
PI(3,4,5)P3 at the plasma membrane which in turn recruits and leads to the activation of 
Akt/PKB serine/threonine kinase, a well known PI3K transduction target (Cantley 2002).  When 
PIK3IP1 binds to p110, PI3K activity and subsequently the activation of Akt/PKB are reduced 
(Zhu et al., 2007).   
 
A 
 
B 
 
Figure 5: PIK3IP1 negatively regulates PI3K activity and activated Akt abundance.  
PI3K activity was assessed in PIK3IP1-C33A (two independent clones) and Vector-C33A (two independent clones) 
cells by conventional PI3K assay using anti-p110 antibody or Ig antibody (negative control) for 
immunoprecipitation (Figure 5A). The average PIP level was calculated, normalized and graphed following 
densitometric analysis for each cell type. * p=0.04. The results are representative of three independent trials 
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carried out in triplicate. Western blot analysis of the PI3K downstream effector Akt (phosphorylated and total) was 
assessed in PIK3IP1- and Vector-C33A cells. pAKT (Thr308) – antibody recognizing the activated form of AKT 
phosphorylated on Thr308 (a site which is phosphorylated specifically in response to PI3K signaling); Total AKT – 
antibody recognizing activated and unactivated forms of AKT; and Beta-actin – antibody used to determine loading. 
Densitometric readings of the western signals were normalized for the PIK3IP1-C33A or Vector-C33A cells; the 
results are shown graphically. (Figure 5B) (Zhu et al., 2007) 
 
In our initial biochemical analyses of PIK3IP1, we noted that PIK3IP1 protein migrated 
variably in SDS-PAGE/Western blot analysis.  We were puzzled as to why this may be so. We 
observed that in vitro transcribed/translated 35S-labeled PIK3IP1 protein measured 37 kDa in 
SDS-PAGE, but the predominant forms of endogenously expressed PIK3IP1 protein in human 
tissues and cell lines had apparent molecular masses of about 43 kDa, 37 kDa, and 22-25 kDa in 
western blot analysis (Zhu et al., 2007).  
To address these issues, we performed several experiments. We determined that PIK3IP1 
is a bone fide membrane bound protein and that PIK3IP1 is a target of serine protease cleavage 
following growth factor- or serum treatment of cells. This latter attribute accounts for the 
appearance of the PIK3IP1 species of about 22-25 kDa.  Next, we found that PIK3IP1 undergoes 
N- and O-linked amino acid glycosylation. The major glycosylated form of PIK3IP1 migrates at 
about 43 kDa in SDS-PAGE/western blot analysis, while the unglycosylated form migrates at 37 
kDa. Thus, our analyses of PIK3IP1 protein have uncovered modifications that may affect its 
ability to act as an inhibitor of PI3K.      
 
2.2 MATERIALS AND METHODS 
2.2.1 Chemicals and reagents. 
A polyclonal antibody was made in a rabbit against a PIK3IP1 antigenic peptide  as 
described previously (Zhu et al., 2007). Secondary antibodies were obtained from Chemicon 
International, Inc. (Temecula, CA).  G418 was obtained from Invitrogen Corporation (Carlsbad, 
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CA). Phenylmethylsulfonyl fluoride (PMSF) was purchased from Sigma-Aldrich (St. Louis, MO) 
and stored in dimethyl sulfoxide (DMSO) at -20°C. 
2.2.2 Cell culture  
C33A, human uterine cervical epithelial carcinoma cells, and HepG2, human 
hepatocellular carcinoma cells, were purchased from ATCC (Manassas, VA).  PIK3IP1-C33A 
and Vector-C33A cells were produced by transfecting in an either an empty expression vector 
(pCR3.1) or one bearing the full length PIK3IP1 human cDNA as described by Zhu et al. (Zhu et 
al., 2007).  All C33A cells were grown in EMEM containing 10% fetal bovine serum; HepG2 
cells were cultured in DMEM containing 10% fetal bovine serum.  Both were typically grown to 
80% confluence. For some studies, cells were serum starved overnight (O.N) before treatment.  
2.2.3 Protein isolation, SDS-PAGE, immunoprecipitation and Western blot 
analysis 
Cells such as C33A or HepG2 were washed twice with cold-PBS (pH 7.5) and lysed with 
RIPA lysis buffer (1X PBS, 1% Igepal CA630 [Sigma Aldrich Corp.], 0.5% sodium 
deoxycholate, 0.1% SDS, 10 µg/ml PMSF, 10 µg of aprotinin/ml, 10 µg of leupeptin/ml, 0.5 µg 
of antipain/ml, and 0.5 µg of pepstatin/ml). Lysates were sonicated, and cellular debris was 
removed by centrifugation at 12,000 rpm for 15 min at 4°C.  Generally, 40 µg of protein were 
analyzed.  2X SDS sample buffer was added to protein lysates which were resolved by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) according to standard 
procedures, transferred to polyvinylidene difluoride (PVDF) membranes, and probed with the 
appropriate primary antibodies, followed by secondary goat anti-mouse, or donkey or goat anti-
rabbit antibodies as indicated. Commercial antibodies were used at the concentrations 
recommended by their manufacturers.  Signals were illuminated by the  Western Lightning 
Chemiluminescence Reagent PLUS (PerkinElmer Inc., Boston, MA, #NEL102)  followed by 
exposure to Biomax film (Eastman Kodak Company, New Haven, CT).   
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2.2.4 Non-detergent cell fractionation 
Both cytosol and plasma membrane enriched fractions were prepared under non-
detergent conditions. Briefly, HepG2 cell lysates were prepared by the standard freeze-thaw 
method in 10mM Tris-HCl (pH 7.5) in the presence of protease inhibitor cocktail (1:100, Sigma-
Aldrich Corp., #p8340). After centrifugation at 17,000 rpm for 3 hr. at 4 oC, the supernatant 
(soluble) containing cytosolic proteins was decanted.  The plasma membrane containing pellet 
(insoluble) was resuspended in 1% SDS in 10 mM Tris-HCl (pH 7.5) in the presence of protease 
inhibitor cocktail. The cytosolic and particulate fractions were then subjected to SDS-PAGE and 
Western blot analysis. 
2.2.5 Deglycosylation assay 
Deglycosylation of PIK3IP1 protein was carried out using the Enzymatic 
Deglycosylation Kit (Glyko/ProZyme, San Leandro, CA, #GK80110) according to the 
manufacturer’s instructions.  Briefly, PIK3IP1-C33A cell lysate (100 µg) was placed in an 
Eppendorf tube containing 30 µl dH2O.  Ten (10) µl 5X Incubation Buffer and 2.5 µl of 
Denaturation Solution were added, and the contents were gently mixed.  The lysate was heated to 
100°C for 5 min. after which it was cooled to RT.  Detergent Solution (2.5 µl) was then added 
followed by 1 µl each of N-Glycanase, Sialidase A or O-Glycanase.  The lysate was then 
incubated for 3 hr. at 37°C and analyzed for mobility shift of PIK3IP1 protein by SDS-
PAGE/Western blot analysis. Densitometric analysis of specific signal was carried out using 
Scion Image 1.63 software (Scion Corporation, Frederick, MD). 
2.2.6 Serum-induced cleavage assays 
To induce PIK3IP1 cleavage, PIK3IP1-C33A cells were serum starved ON; cells were 
harvested in RIPA buffer after exposing them to either medium containing 10% fetal bovine 
 11 
serum or serum free medium from 0 to 30 min.  The reaction was stopped by the addition of SDS 
sample buffer; then, samples were subjected to SDS-PAGE and Western blot analysis. 
2.2.7 Serine protease inhibition assay  
To inhibit serine proteases, PIK3IP1-C33A cells were incubated at 37 oC in medium 
containing either 1 mM PMSF in DMSO or DMSO alone as a control for 4 hr. The cells were 
lysed with RIPA buffer, and samples were subjected to SDS-PAGE and Western blot analysis.    
2.2.8 Ras activity assay 
Ras activity was compared between C33A-PIK3IP1 and C33A vector cells by using Raf-
RBD domain protein agarose beads (Upstate Biotechnology, Lake Placid, NY), which measure 
the GDP/GTP ratio of Ras in vitro.    
2.2.9 Statistical analysis  
Stasticial analysis was carried out using the two tailed Student’s t-test. Values were 
considered to be statistically different when the p-value was less than 0.05, and such values are 
indicated in the figures with asterisks.   
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2.3 RESULTS AND DISCUSSION 
2.3.1 Characterization of the PIK3IP1 protein 
We examined HepG2 cell lysates by western blot for endogenous PIK3IP1 protein.  We 
found that HepG2 cells express PIK3IP1 proteins measuring approximately 65 kDa, 43 kDa, and 
22-25 kDa and that these variants of PIK3IP1 are all associated with the insoluble particulate 
fraction upon cell fractionation (Figure 6). Similar results were obtained with PIK3IP1-C33A 
cells, human cervical carcinoma cells engineered to overexpress PIK3IP1, although a 37 kDa 
variant was more prominent and the 65 kDa variant was undetectable in these cells as compared 
to HepG2 cells (data not shown). These findings suggested to us that PIK3IP1 is indeed 
membrane bound and that these variants arise from alternative splicing and/or post-translational 
processing events such as enzymatic proteolysis and/or glycosylation. 
 
 
Figure 6: PIK3IP1 is a membrane protein.    
HepG2 cells were fractionated into soluble and insoluble components under non-detergent conditions.  
PIK3IP1 was found to associate with the insoluble membrane-containing fraction by Western blot analysis 
indicating that it is membrane-bound.  Specific PIK3IP1 protein bands of 65, 43, 22-25 kDa were identified in the 
insoluble fraction.  Beta actin was used as a loading control.   Total – unfractionated input lysate 
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2.3.2 PIK3IP1 suppresses Ras activity 
Cross-talk between the PI3K/Akt and Ras/Raf/Erk pathways has been reported. Since 
PIK3IP1 negatively regulates PI3K (Zhu et al., 2007), as well as Erk MAPK and p38 MAPK 
(data not shown), we were curious as to whether PIK3IP1 could also negatively regulate Ras. To 
confirm our hypothesis, Raf-RBD domain protein agarose beads were used to measure the 
GTP/GDP ratio of Ras in vitro. We observed that C33A cells with high expression of PIK3IP1 
showed an obvious reduction in Ras kinase activity in pull-down assay with Raf-RBD domain 
protein (Figure 7). This result, together with our observations that PIK3IP1 inhibits Erk/p38 
MAPK suggests that PIK3IP1 inhibits the Ras pathway too. Whether the effect of PIK3IP1 on 
Ras is direct or indirect through PI3K is unknown. The goal of future experiments is to fully 
characterize this relationship. 
 
 
Figure 7: PIK3IP1 suppresses Ras activity.  
Ras activity was compared between C33A-PIK3IP1 and C33A vector cells. 
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2.3.3 PIK3IP1 protein is cleaved by a serine protease induced by serum or growth 
factor treatment 
Some kringle containing proteins, such as hepatocyte growth factor (HGF), are targets of 
serine proteases (Mars et al., 1993). We entertained the possibility that PIK3IP1 protein which 
has a kringle in its extracellular domain is likewise targeted for enzymatic cleavage given the 
identification of both higher (43 and 37 kDa) and lower (22-25 kDa) molecular weight PIK3IP1 
species (Figure 6) in Western blot analysis.   
To evaluate the possibility that PIK3IP1 protein is a target for enzymatic cleavage, we 
determined whether addition of serum (10%) which is known to contain a variety of proteases, 
some of which are involved in enzymatic activation of kringle bearing proteins, promotes the 
appearance of the lower molecular PIK3IP1 species in PIK3IP1-overexpressing C33A cells. In 
Figure 8, we observed that addition of serum to quiescent cells in a time course analysis resulted 
in the appearance of the lower molecular weight PIK3IP1 species within 5 min. consistent with 
the notion that PIK3IP1 protein cleavage is stimulated by addition of serum.   
As mentioned above, we postulated that the cleavage of PIK3IP1, like other kringle 
containing proteins, is carried out by a serine protease. If this were to be true, the serine protease 
inhibitor, PMSF, should inhibit PIK3IP1 cleavage. In the presence of PMSF, PIK3IP1 cleavage 
induced by serum addition to PIK3IP1-C33A cells was significantly suppressed as compared to 
control conditions (Figure 9) suggesting that a serine protease is responsible for PIK3IP1 protein 
processing. We are currently attempting to determine the exact cleavage site in PIK3IP1’s 
extracellular domain and to identify the responsible cleavage enzyme. 
 
 
 
 
 
 
 
 15 
 
 
              Figure 8: Serum addition induces PIK3IP1 cleavage in PIK3IP1-C33A cells.   
Addition of serum (10%) to quiescent PIK3IP1-C33A cells for the indicated times resulted in the appearance of the 
lower molecular weight species of PIK3IP1 of about 22 kDa as early as 5 min. post-induction.   
 
 
 
 
            Figure 9: PIK3IP1 cleavage is PMSF sensitive.  
PIK3IP1-C33A cells were incubated O.N. at 37°C with the serine protease inhibitor PMSF (1 mM final 
concentration) or its solvent DMSO. The cells were lysed with RIPA lysis buffer and analyzed by Western blot for 
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PIK3IP1 and Beta actin (as a loading control).  The data were analyzed by densitometry and normalized.  The 
relative abundance of cleaved PIK3IP1 to uncleaved PIK3IP1 is shown in the graph.  Values of statistical 
significance are shown with an asterisk.    
 
2.3.4 PIK3IP1 protein is glycosylated on O- and N-linked amino acid residues 
To explore whether PIK3IP1 is glycosylated, we examined the human PIK3IP1 amino 
acid sequence with NetNGly 1.0 search engine (http://www.cbs.dtu.dk/services/NetNGlyc/) 
(Blom et al., 2004).  It predicted the existence of a single putative N-glycosylation site in the 
extracellular portion of PIK3IP1 at residue 66 (Asn) with an N-glycosylation potential of about 
65% (pink stealth arrow—Figure 4). This Asn residue is conserved in human, mouse and rat.   
To search for O-glycosylation sites in PIK3IP1 protein, we used the YinOYang 1.2 search engine 
(http://www.cbs.dtu.dk/services/YinOYang/). Several putative residues that have O-
glycosylation potential were identified in the extracellular portions of the human, mouse and rat 
PIK3IP1 proteins; however, the residue showing the highest average potential (62%) among the 
species was residue 106 (Ser) (black solid arrow—Figure 4).   
Next, we carried out enzymatic deglycosylation of PIK3IP1 protein in lysate from 
overexpressing human PIK3IP1-C33A cancer cells using the Enzymatic Deglycosylation Kit 
(Glyko/Prozyme) according to the manufacturer’s instructions. We found that the 43 kDa species 
of PIK3IP1 underwent deglycosylation following treatment with either N- or O-glycanase to an 
apparent molecular mass of about 40 kDa (Figure 10). However, when N- and O-glycanase were 
added in combination, the apparent molecular mass of PIK3IP1 shifted to about 37 kDa 
suggesting that PIK3IP1 protein undergoes both N- and O-glycosylation in vivo which accounts 
for the major high molecular weight (i.e. 43 kDa) PIK3IP1 form we observe in various human 
tissues and cell lines.   
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        Figure 10: PIK3IP1 protein is glycosylated on N- and O-linked amino acid residues. 
Enzymatic deglycosylation of PIK3IP1 protein in lysate from PIK3IP1-overexpressing human cancer cells 
(PIK3IP1-C33A) was performed.  The 43 kDa species of human PIK3IP1 protein underwent deglycosylation 
following treatment with either N- or O-glycanase alone to an apparent molecular mass of about 40 kDa.  However, 
when N- and O-glycanases were added in combination, the apparent molecular mass of PIK3IP1 shifted to about 37 
kDa.  Mock – input protein treated identically except no enzyme was added.  
 
 
In conclusion, we confirmed that PIK3IP1 is a membrane protein which undergoes post-
translation modifications including glycosylation and cleavage. Furthermore, in addition to 
curbing PI3K pathway by direct binding, PIK3IP1 can also suppress Ras activity. This may 
occur indirectly through its effect on PI3K and/or MAPK.  
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3.0  PIK3IP1 SUPPRESSES THE DEVELOPMENT OF HEPATOCELLULAR 
CARCINOMA  
3.1 INTRODUCTION 
Abnormalities in PI3K-AKT signaling contribute to the pathogenesis of several human 
cancers. For example, gain-of-function mutations in the PI3K catalytic subunit (p110 
alpha/PIK3CA) were frequently identified in cases of human ovarian carcinomas and breast 
carcinomas (Lee JW et al., 2005), whereas loss-of-function mutations in PTEN, a negative 
regulator of the PI3K signaling pathway, were reported in a variety of human cancers such as 
melanoma (Celebi JT et al., 2000; Zhou X et al., 2000) and endometrial carcinomas (Salvesen H 
et al., 2001), suggesting an important role of aberrant PI3K signaling in tumorigenesis of the 
liver and other tissues. 
Abnomalities in the PI3K pathway were also detected in human HCC. For example, of 
the various tumor types tested, liver cancer shows the highest percentage of cases with pik3ca 
mutations (36%) (Engelman et al., 2006). Another PI3K pathway constituent that is targeted in 
liver cancer is PTEN (phosphatase and tensin homologue). PTEN is the product of a well-known 
tumor suppressor gene and acts as a lipid and protein phosphatase that regulates the relative 
cellular concentration of PI(3,4,5)P3 (Maehama et al., 1999). PTEN protein abundance is 
downregulated in human HCC (Hu et al., 2003; Wan et al., 2003). Mutations and loss of 
heterozygosity of the PTEN gene (Fujiwara et al., 2000) have been identified as well.  
Experimentally, liver tumors developed in mice lacking functional PTEN in hepatocytes (Horie 
et al., 2004).   
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Considering the high level of PI3K activity in HCC, we hypothesized that overexpression 
of PIK3IP1 in hepatocytes could alter the natural activity of the PI3K pathway as well as 
hepatocellular carcinoma development in this tissue. To test this hypothesis, we developed a 
PIK3IP1 TG mouse model directing expression of PIK3IP1 to hepatocytes under the regulatory 
control of the albumin promoter. The genetic background of our TG mice is C3H, a strain which 
spontaneously develops HCC at a high incidence (reportedly 72-91% in males by 14 months). 
Therefore, in the present study, we investigated the role of PIK3IP1 as a tumor suppressor in 
mouse hepatocarcinogenesis by using our PIK3IP1-C3H TG mouse model. First, we show that 
PIK3IP1 overexpression suppresses HCC turmorigenesis in C3H mice. Second, we found that 
Ki67 labeling index is reduced by 3 fold in TG mouse hepatocytes in vivo. Finally, we 
demonstrate that in isolated hepatocytes, PI3K activity and signaling, proliferation, survival and 
motility/migration are all significantly reduced in TG mice as compared to control animals.  Our 
results indicate that PIK3IP1 is a novel tumor suppressor and may play an important role in 
hepatocarcinogenesis. 
3.2 MATERIALS AND METHODS 
3.2.1 Chemicals and reagents 
The following reagents were described previously:  polyclonal antibody against PIK3IP1, 
anti-p110 antibodies, anti-phospho-Akt and anti-Akt antibodies as well as Protein-A agarose and 
IgG control antibody (Zhu et al., 2007).  Mouse epidermal growth factor (EGF) was purchased 
from BD Biosciences (Mountain View, CA). Hepatocyte growth factor (HGF—five amino acid 
deleted isoform) was a kind gift from Snow Brand Milk Products, Ltd. (Japan). Ly294002 was 
purchased from LC Laboratories (Woburn, MA).  All other chemical reagents were obtained 
from Sigma Chemical Company (St. Louis, MO) unless otherwise noted.  
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3.2.2 Assurances 
Appropriate University of Pittsburgh Institutional Review Board (IRB), Institutional 
Animal Care and Use Committee (IACUC) and Recombinant DNA (rDNA) approvals were 
obtained prior to commencing these studies. 
3.2.3 Generation and characterization of liver specific PIK3IP1 transgenic mice 
A 0.8 kb mouse PIK3IP1 cDNA containing the entire coding region of PIK3IP1 was 
derived from a mouse mammary gland est (GenBank I.D.: AA754893).  PCR primers (forward 
primer: 5’-TTAGGATCCCATTTGGACACTGGCTG-3’; reverse primer:  5’-
GATCCTAGGCCTGTACCAGTGTTTAC-3’) were prepared that incorporated BamHI sites in 
the 5’ and 3’ non-coding regions of the cDNA near the translation stop and start codons, 
respectively.  The amplified region was inserted into the BamHI site of an albumin promoter-
driven expression vector which was kindly provided by Dr. Richard Palmiter (University of 
Washington, Seattle, Washington) as described by Bell et al. (Bell et al., 1999). This transgene 
was used to generate TG mice on a B6SJL background at the Duke University Medical Center 
Transgenic Mouse Facility (Durham, NC).  TG mice were identified by Southern blot analysis 
(using standard procedures) of BamHI digested genomic tail DNA using a 32P-labeled 0.8 kb 
mouse PIK3IP1 cDNA probe.  To confirm the results, PCR analysis of blood DNA was 
performed using oligonucleotide primers designed from the PIK3IP1 gene as follows:  forward 
primer:  5'-GACGTGAGTTGCCCAGAGACC-3'; reverse primer:  5'-
TTACCTGCAGCCATTGCCGCTAGTGAG-3'. TG mice were propagated by breeding with 
wildtype C3H mice for greater than four generations.   
 
3.2.4 Mouse tumor tissues  
Livers of young mice (<6 mo.) were harvested, and liver and body weights were recorded 
to calculate the liver:body weight ratio. Grossly, the livers appeared to be normal in the TG and 
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non-transgenic (NTG) animals, and the liver:body weight ratios were similar between the two 
groups.  Histologically, major architectural changes attributable to the presence of the PIK3IP1 
transgene were not observed.   
For mouse tumor studies, eight male TG and eight male NTG littermates (average age 14 
mo.) were sacrificed by cervical dislocation and necropsied.  Gross examination of the liver for 
tumors was performed.  The presence of grossly visible tumor was documented.  A portion of 
each liver lobe was placed in formalin, embedded, sectioned and stained with H&E.  Tissue 
sections were examined histologically to confirm the presence of hepatocellular carcinoma.  The 
remaining liver tissue was snap frozen for additional experimentation.  Ki67 and TUNEL 
immunostaining of formalin fixed liver using standard procedures was performed to assess 
hepatocyte proliferation and apoptosis, respectively.  The Ki67 antibody was purchased from 
Abcam (Cambridge, MA) and used at a concentration of 1:50.  The DeadEnd™ Colorimetric 
TUNEL System (Promega Corporation, Madison, WI) was used to evaluate apoptosis.  Three to 
five thousand hepatocyte nuclei in non-tumorous tissues were examined per animal following 
Ki67 or TUNEL staining.  The formula used to determine the Ki67 or apoptotis indices was:  
number of Ki67 or TUNEL positive hepatocyte nuclei, respectively, divided by the total number 
of hepatocyte nuclei counted.   
 
 
3.2.5 Protein isolation, SDS-PAGE and Western blot analyses 
Human and mouse liver tissues as well as isolated mouse hepatocytes were subjected to 
western blot (WB) analysis as described previously (Zhu et al., 2007).  Commercially available 
antibodies were utilized at the dilutions recommended by their manufacturers.  Western 
Lightning Chemiluminescence Reagent PLUS (PerkinElmer Inc., Boston, MA, #NEL102) and 
Biomax film (Eastman Kodak Company, New Haven, CT) were used to detect the WB signals, 
the intensities of which were measured using Scion Image 1.63 software (Scion Corporation, 
Frederick, MD).  
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3.2.6 In vitro PI3K activity assay 
PI3K activity assays were performed as previously described (Zhu et al, 2007). Briefly, 
protein lysates (1 mg) were immunoprecipitated with anti-p110 antibodies, washed 3X with 
RIPA buffer, followed by three washes with PI3K reaction buffer (PI3K-RB) (20 mM Tris-HCl, 
pH 7.4, 100 mM NaCl, and 0.5 mM EGTA).  Immunoprecipitates were suspended in 50 µl of 
PI3K-RB containing 0.2 mg/ml phosphatidylinositol (PI, Sigma) followed by incubation for 10 
min. at RT.  After incubation at RT, 440 µl of PI3K-RB containing 30 µCi of 32P-gammaATP, 
0.88mM ATP and 20 mM MgCl2 was added to the resuspended immunoprecipitates  which were 
then incubated for 10 min. at RT.   100 µl of chloroform:methanol:HCl (200:100:2) was used to 
halt the reaction. Thin layer chromatography was used to separate the products in 
chloroform:methanol:ammonium hydroxide:water (86:76:10:14) running buffer. Lysates were 
routinely assessed for p110 abundance by IP and WB analysis.    
 
3.2.7 Isolation and culture of primary mouse hepatocytes.  
Mouse hepatocytes were isolated from male PIK3IP1 TG and NTG littermates by the in 
situ two-step collagenase perfusion technique described previously (Bell et al., 1999). 
Hepatocytes were pelleted by centrifugation, assessed for viability by Trypan Dye exclusion 
which typically ranged from 70 – 90%, and cultured in Eagle’s Minimal Essential Medium 
(EMEM—Cellgro, Herndon, VA) containing 10% fetal bovine serum.  The medium was then 
changed to serum free after 3 hr.    For some experiments, hepatocytes were plated in hepatocyte 
growth medium (HGM (12)) with slight modification as follows:  1) EMEM was used in place of 
Dulbecco’s Modified Essential Medium; 2) nicotinamide was omitted; and 3) dexamethasone 
was added at a final concentration of 10-8M.   
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3.2.8 3H-thymidine incorporation assay  
Mouse hepatocytes from either TG or NTG littermates were seeded at 250,000 cells per 
well in 6 well plates in triplicate in HGM.  Following 18 hr. under serum free conditions, the cells 
were changed to HGM medium containing 2.5 μCi 3H-thymidine with or without a combination 
of HGF (30 ng/ml) and EGF (25 ng/ml) and with either Ly294002 (10 µM in DMSO) or DMSO 
alone as a vehicle control.  After 48 hr., radioactivity was measured by scintillation counting as 
described (DeFrances et al., 1992).  
 
3.2.9 Transwell migration assay 
Transwell migration assays were performed on hepatocytes as described previously 
(Stolz et al., 1994). Briefly, TG or NTG hepatocytes were seeded onto the upper part of a 12 μm 
pore Transwell chamber (collagen I coated) at a density of 50,000/cm2 and allowed to attach for 
3 hr. Unattached cells were washed; adherent cells were maintained in serum-free EMEM for 12 
hr. prior to transfer of the Transwell to a fresh 12-well plate containing EGF (20 ng/ml) or 
control media with either Ly294002 (10 µM in DMSO) or DMSO alone as a vehicle control. 
Cells were then allowed to migrate for 24 hr. prior to fixing with 4% paraformaldehyde in PBS 
for 30 min. Cells were then stained with 0.1% Coomassie blue in 10% methanol/10% acetic acid 
for 1 hr. Transwells were washed; stationary cells were removed from the filter top with a 
cotton-tipped applicator; cell debris was washed away; then, cells that had migrated to the 
bottom of the Transwell filter were enumerated by counting ten fields for each Transwell at 
200X magnification.  
 
3.2.10 In vitro scratch assay 
One million TG or NTG hepatocytes were seeded in 6-well plates to obtain confluent 
monolayers. After 12 hr., a scratch to dislodge cells was made in the monolayers using a blunted 
 24 
Pasteur pipette, and hepatocytes were washed several times to remove floating cells and debris. 
Cultures were treated with or without EGF (20 ng/ml) and with either Ly294002 (10 µM in 
DMSO) or DMSO alone as a vehicle control for up to 5 days.  The medium was changed daily.  
3.2.11 UV-induced apoptosis assay 
1x105 TG or NTG hepatocytes were cultured for 12 hr. on single well chamber slides (9.4 
cm²/well—Lab-Tek, Germany). Some slides were treated with a dose of 50 J/m2 UV irradiation 
without medium. Mock treatment consisted of medium removal for an equivalent time period but 
no UV exposure. Serum free medium was replaced, and after 24 hr., slides were fixed with 4% 
paraformaldehyde and TUNEL stained for detection of apoptotic cells.  Cleaved caspase 3 was 
assessed by WB using cell lysates harvested from some cultures.    
 
3.2.12 Statistical analysis 
Statistical analysis was carried out using a two-tailed Student’s t-Test unless otherwise 
specified. Results were considered to be statistically significant when p values were determined 
to be less than 0.05.   
3.3 RESULTS 
3.3.1 Generation and characterization of hepatocyte-specific PIK3IP1 
overexpressing mice.  
We subcloned the full-length mouse PIK3IP1 cDNA into a construct containing the 
human growth hormone gene under the transcriptional  control of the mouse albumin 
promoter/enhancer (Figure 11) as we described previously for human HGF (Bell et al., 1999) and 
generated transgenic mice. We utilized this particular promoter/enhancer cassette because 
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albumin promoter activity is specific for hepatocytes, rises after birth and plateaus within 
approximately one month (Tilghman et al., 1982).  
 
 
 
 
 
             Figure 11:  PIK3IP1 transgene construct. 
Full-length mouse PIK3IP1 cDNA was subcloned into an albumin promoter/enhancer growth hormone expression 
construct.   
 
 
 
3.3.2 PIK3IP1 expression reduces PI3K activity and phospho-Akt levels in mouse 
liver. 
We first ascertained that TG mice overexpress PIK3IP1 in the liver by qRT-PCR (Figure 
12) as compared to controls.  We noted no differences in p110 alpha or beta protein levels 
between the livers of TG and NTG mice (data not shown). However, we did observe a significant 
diminution in PI3K activity by about 50% (data not shown) and a marked decrease in phospho-
Akt levels by western blot (Figure 13) in the TG livers as compared to controls suggesting that 
PIK3IP1 regulates p110 activity and signaling in liver.  
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Figure 12: PIK3IP1 mRNA expression is increased in PIK3IP1 TG mouse livers.  
 Total liver RNA from transgenic (TG—n = 13) and non-transgenic (NTG—n = 16) mice was subjected to qRT-PCR.  
Data were normalized to 18S rRNA; the relative fold change in PIK3IP1 mRNA abundance was calculated and 
graphed.  *p=0.000023  
 
 
 
Figure 13: Phospho-Akt is downregulated in PIK3IP1 transgenic mouse liver.   
Western blot (WB) analysis of liver protein lysates from transgenic (TG—n = 2) and non-transgenic 
(NTG—n = 2) littermates was carried out using antibodies to phospho-Akt and total Akt.  Beta Actin was used as a 
loading control.   
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3.3.3 PIK3IP1 downregulates Akt in isolated mouse hepatocytes    
To further investigate PIK3IP1’s effects on liver cell biology and the PI3K pathway, we 
isolated hepatocytes from TG and NTG animals. We confirmed that PIK3IP1 is overexpressed in 
the TG hepatocytes as compared controls by qRT-PCR (data not shown). Next, we examined the 
hepatocytes for basal Akt activation by WB and detected decreased levels of endogenous 
phospho-Akt in cultured TG hepatocytes as compared to control cells (Figure 14).  This indicates 
that PIK3IP1 expression does indeed downregulate the PI3K pathway in TG hepatocytes.   
 
 
Figure 14: Phospho-Akt is dampened in PIK3IP1 transgenic mouse hepatocytes.   
Transgenic (TG) and non-transgenic (NTG) cultured mouse hepatocytes were subjected to western blot 
(WB) analysis using anti-phospho-Akt and total Akt antibodies.  Beta Actin was used as a loading control.      
 
 
3.3.4 PIK3IP1 suppresses mouse hepatocyte DNA synthesis and motility in culture  
 Since we determined that PIK3IP1 reduces signaling through the PI3K pathway in TG 
hepatocytes and since PI3K activity is linked to increased cell motility and proliferation in a 
wide variety of cell types, we next explored the functional consequences of PIK3IP1 expression 
and PI3K downregulation on DNA synthesis and motility in the TG and NTG hepatocytes.  
When cultured hepatocytes were induced to undergo DNA synthesis by addition of known 
hepatic mitogens (HGF and EGF) (Michalopoulos et al., 2005), the DNA synthetic response in 
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TG hepatocytes measured by fold increase in 3H-thymidine incorporation over control cultures 
was strongly impaired (Figure 15).  We also added Ly294002 (LY), a known PI3K inhibitor 
(Vlahos et al., 1994), to some cultures to determine the effect of PI3K inhibition on hepatocyte 
DNA synthesis; LY treatment also blunted growth factor-induced hepatocyte DNA synthesis 
(data not shown).  Overall, our results demonstrate that PIK3IP1 expression diminishes mouse 
hepatocyte DNA synthetic activity likely through inhibition of PI3K signaling.   
 
Figure 15:  DNA synthesis is blunted in PIK3IP1 transgenic mouse hepatocytes.   
Transgenic (TG) and non-transgenic (NTG) cultured mouse hepatocytes were stimulated to undergo DNA 
synthesis by addition of HGF and EGF (GF; Control = no growth factor added).  A standard 3H-thymidine (3H-θ) 
incorporation assay was performed in triplicate.  The relative fold change in average 3H-thymidine incorporation 
over control cultures was assessed. *p=0.01 This assay was repeated with hepatocytes isolated from a different set 
of animals and had a similar outcome. 
 
 
To examine the effect of PIK3IP1 on cell motility, another cellular function ascribed to 
PI3K (Keely et al., 1997), we subjected TG and NTG hepatocytes to a transwell migration assay.   
In response to EGF, a well-characterized hepatocyte motogen (Stolz et al., 1994), three fold 
fewer TG hepatocytes than NTG hepatocytes migrated across the transwell insert (mean number 
of migrated hepatocytes per hpf:  23.8 + 13.8 vs. 70.3 + 22.5, respectively (Figures 16A&B). 
This difference was found to be statistically significant (p=0.00003).  As a control for PI3K 
inhibition, LY was added to some EGF-treated TG and NTG cultures; LY reduced migration of 
both cell types by over two fold (Figures 16A&B).   
 
 29 
 
 
Figure 16: Hepatocyte migration is reduced by PIK3IP1:  transwell migration assay. 
  A transwell migration assay was performed using transgenic (TG) and non-transgenic (NTG) plated at a 
density of 50,000/cm2.  Migration was stimulated by addition of EGF.  Some cultures were also treated with 
Ly294002 (LY—a PI3K inhibitor).  Hepatocytes that migrated to the underside of the transwell insert were stained 
with Coomassie blue, enumerated and photographed; the images are shown in A.  The mean number of migrated 
hepatocytes per high power field (hpf) is graphed in B. *p<0.01 Control = no growth factor added. This assay was 
repeated with hepatocytes isolated from a different set of animals and had a similar outcome. 
 
In parallel, we performed a second type of motility assay (i.e., an in vitro scratch assay 
(Liang et al., 2007)) which compares the ability of TG and NTG hepatocytes to reepithelialize a 
scratched surface.  As shown in Figure 17, reepithelialization was significantly delayed in TG 
hepatocyte cultures as compared to controls which typically reconstituted the void in 5 days in 
our assay.  We added LY to some EGF-treated cultures; it halted reepithelialization by both TG 
and NTG hepatocytes. Taken together, our data indicate that PIK3IP1 impedes mouse hepatocyte 
motility, a response that is likely to be at least in part PI3K dependent. 
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Figure 17: Hepatocyte migration is reduced by PIK3IP1:  in vitro scratch assay.    
An in vitro scratch assay was carried out using transgenic (TG) and non-transgenic (NTG) cultured mouse 
hepatocytes.   Migration was stimulated by addition of EGF.  Some cultures were also treated with Ly294002 (LY—
a PI3K inhibitor).  Restitution of the scratched surface was observed over five days.  The photographs shown were 
taken at days 3 and 5 post-scratch.  Control = no growth factor added. This assay was repeated with hepatocytes 
isolated from a different set of animals and had a similar outcome.   
 
 
3.3.5 PIK3IP1 promotes apoptosis in isolated mouse hepatocytes. 
 Considering the key role of PI3K in cell survival (Downward et al., 2004), we next 
assessed if PIK3IP1 spurs hepatocyte cell death.  To do so, we induced apoptosis in TG and 
NTG hepatocytes with UV exposure and examined the cells for apoptosis by TUNEL staining 
and by western blot (WB) for cleaved caspase 3.  Normal cultured hepatocytes are known to 
undergo apoptosis upon UV treatment (Prost et al., 1998).  In our experiments, we observed that 
47.4 + 6.3% of TG hepatocytes and only 28.5 + 3.3% of control cells became TUNEL positive 
48 hr. following UV irradiation (Figures 18A&B) which was determined to be a statistically 
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significant difference (p=0.00005). TG hepatocytes also showed significantly more cleaved 
caspase 3 by WB at this time point when compared to NTG cells (Figure 18 C).  Taken together, 
these data support the idea that PIK3IP1 promotes apoptosis in isolated hepatocytes, an 
observation that is in agreement with our previous finding that PIK3IP1 enhanced apoptotic cell 
death induced by staurosporine addition to C33A human endometrial cancer cells (Zhu et al., 
2007).   
 
 
 
Figure 18: PIK3IP1 augments hepatocyte apoptosis.   
 
Transgenic (TG) and non-transgenic (NTG) cultured mouse hepatocytes were induced to undergo 
apoptosis with ultraviolet light (UV – 50 J/m2) or mock treatment.   A)  TUNEL assay.  The cells were fixed, 
immunostained for TUNEL and photographed.  TUNEL positive hepatocyte nuclei are indicated with arrows in A.  
The apoptotic rate was calculated and graphed (B).  This assay was repeated with hepatocytes isolated from a 
different set of animals and had a similar outcome.  C)  Measurement of cleaved caspase-3 by Western Blot.  
Transgenic (TG) and non-transgenic (NTG) cultured mouse hepatocytes were induced to undergo UV-induced 
apoptosis as above.  Protein lysates were prepared and subjected to western blot (WB) for cleaved caspase 3.  Beta 
actin was used as a loading control.     
 
 32 
3.3.6 PIK3IP1 suppresses hepatocyte proliferation and spontaneous HCC 
development in vivo 
Once we established that PIK3IP1 overexpression alters PI3K activity in mouse liver and 
in isolated hepatocytes, we wanted to determine whether its presence affects the appearance of 
liver tumors in vivo. Our transgenics were crossed onto a C3H background.  Male mice of the 
C3H strain spontaneously develop hepatocellular carcinoma (HCC) without carcinogen 
treatment:  the incidence of liver tumors is estimated to be 72-91% in males at 14 months of age 
(http://jaxmice.jax.org/strain/000659.html).  On necropsy, we found that 62.5% of NTG male 
mice (avg. age 14 mo.) had histologically confirmed HCC in their livers while only 12.5% of 
PIK3IP1 matched male TG littermates developed HCC (Figures 19A&B).  This comparison was 
statistically different (p=0.0387) between the groups using Chi-squared analysis.   
 
To begin to decipher how PIK3IP1 impacts liver tumorigenesis in our animals, we 
examined the hepatocyte proliferation rate in the adjacent livers of TG and NTG mice utilized in 
the tumor study.  We immunostained their livers for Ki67, a nuclear antigen which appears in 
G1-GM.  We observed that about 1.00 + 0.52% of NTG hepatocyte nuclei stained for Ki67 while 
only 0.36 + 0.21% of TG hepatocyte nuclei were Ki67 positive (Figures 19C&D).  This 
difference was found to be statistically significant between the two groups using the Mann-
Whitney test (p<0.0039). The percentage of apoptotic hepatocytes as determined by TUNEL 
staining was not statistically different between the NTG and TG groups (0.27 + 0.15% vs. 0.44 + 
0.32%, respectively) using the Mann-Whitney test. Collectively, these data indicate that the 
presence of PIK3IP1 in hepatocytes suppresses hepatocyte proliferation in vivo and spontaneous 
liver tumorigenesis.   
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Figure 19: PIK3IP1 expression suppresses spontaneous tumorigenesis and 
hepatocyte proliferation in mouse liver.  
A&B)  Spontaneous liver tumor development is inhibited in PIK3IP1 transgenic mice.  Graphic 
representation (A) showing the percentage of PIK3IP1 transgenic (TG—n = 8) and non-transgenic (NTG—n = 8) 
control mice with liver tumors (avg. age = 14 mo.).  *p = 0.0387.  Gross images of representative livers are shown 
in B.  A liver tumor is indicated by the arrow.  C&D) Hepatocyte proliferation is reduced in PIK3IP1 transgenic 
mouse liver.  Adjacent non-tumorous liver tissue from the transgenic (TG) and non-transgenic (NTG) mice 
described in A&B was subjected to immunostaining for the Ki67 proliferation marker.  Representative histologic 
images are shown in C.  The Ki67 positive (indicated by arrows) and negative hepatocyte nuclei were enumerated, 
and the Ki67 proliferation index was calculated and graphed (D). *p = 0.0039.   
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3.4 DISCUSSION  
Unregulated signaling through the PI3K pathway is linked to the development of certain 
types of cancer including hepatocellular carcinoma (Engelman et al., 2006; Lee JW et al., 2005).  
While others have demonstrated that hepatocyte specific gene deletion of the PI3K signaling 
regulator PTEN results in the appearance of liver tumors in a mouse model (Horie et al., 2005), 
no studies of which we are aware have examined the effects of directly suppressing PI3K activity 
on liver tumor development. Our laboratory discovered and characterized a novel negative 
regulator of Class Ia PI3Ks called Phosphatidyl inositol-3-kinase interacting protein 1 (PIK3IP1).  
PIK3IP1 is a transmembrane protein that possesses a region in its intracellular domain that shares 
homology with the p85 regulatory subunit of PI3K.  Previously, we showed through a variety of 
in vitro experiments that PIK3IP1 binds to the p110 catalytic subunit of PI3K through PIK3IP1’s 
intracellular p85-like domain to downregulate PI3K activity (Zhu et al., 2007).   However, we 
had not elucidated the role of PIK3IP1 in controlling PI3K activity in vivo.  The liver requires 
sufficient PI3K signaling to function appropriately.  For example, mice lacking all isoforms of 
p85 alpha (thus showing substantially reduced PI3K activity because of a destabilizing effect on 
p110) die perinatally partly due to liver necrosis (Fruman et al., 2000).   As mentioned, 
unfettered PI3K signaling also alters liver homeostasis.  Aberrant PI3K signal transduction is 
implicated in liver tumorigenesis in both humans and rodents (Lee et al., 2005; Hu et al., 2003; 
Wan et al., 2003; Horie et al., 2005).  Given all of this information as well as our own published 
observations that PIK3IP1 negatively regulates the PI3K pathway in vitro, we wanted to 
ascertain whether PIK3IP1 is involved in normal liver growth and hepatic tumorigenesis.  We 
hypothesized that  PIK3IP1 expression in hepatocytes suppresses PI3K activity in these cells and 
thereby inhibits hepatocyte growth, motility and liver tumorigenesis.    
To test this hypothesis, we took a gain-of-function approach and generated transgenic 
mice in which PIK3IP1 expression is directed to the hepatocytes.  Our decision to target PIK3IP1 
expression to hepatocytes is supported by physiologically relevant evidence summarized as 
follows:  1) the liver has high endogenous PI3K activity as compared to other tissues (data not 
shown), 2) liver survival is dependent on a functioning PI3K pathway (Fruman et al., 2000), 3) 
PIK3IP1 mRNA and protein are expressed by liver and hepatocytes ((Zhu et al., 2007) and data 
not shown, respectively); and 4) the expression levels of PI3K pathway constituents (Lee et al., 
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2005; Hu et al., 2003; Wan et al., 2003; Horie et al., 2005) are altered in human liver tumors as 
compared to adjacent liver.   
Analysis of our PIK3IP1 expressing mice revealed that hepatic PI3K activity is reduced 
as compared to control animals supporting an in vivo role for PIK3IP1 as a PI3K regulatory 
molecule.  Hepatocytes isolated from these animals showed a blunted response to growth factor 
induced DNA synthesis.  In addition, we found that LY294002 (LY), a known PI3K inhibitor, 
stifled DNA synthesis in isolated mouse hepatocytes, a finding that is in agreement with studies 
by others showing that PI3K blockade by wortmannin (another well-studied PI3K inhibitor 
(Kanai et al., 1993)) cuts HGF-induced DNA synthesis in cultures of rat hepatocytes by about 
half as compared to HGF treatment alone (Skouteris et al., 1996).  Given the fact that the 
hepatocyte DNA synthetic response stimulated by growth factors is sensitive to PI3K inhibition, 
it is reasonable to postulate that PIK3IP1’s suppressive effect on this process is mediated by its 
ability to downregulate PI3K activity.   
Growth factors such as EGF or HGF stimulate hepatocyte motility in culture.  Nakanishi 
et al. (Nakanishi et al., 1999) reported that blocking PI3K signaling with wortmannin mitigated 
HGF-induced motility of human liver cancer cell lines in culture; however, it is unknown 
whether the motility of normal hepatocytes depends on signal transduction through the PI3K 
pathway.  Our experiments are the first to demonstrate that normal mouse hepatocytes treated 
with LY are significantly less motile than controls in transwell and scratch assays suggesting that 
hepatocyte motility does indeed rely at least in part on intact PI3K signaling.  In the same types 
of studies, we found that, akin to our observations in LY treated hepatocytes, motility in PIK3IP1 
overexpressing TG hepatocytes was reduced compared to controls which may well be a 
consequence of its ability to suppress PI3K.    
In our animal model, we observed a significant reduction in spontaneous liver 
tumorigenesis in PIK3IP1 overexpressing TG male mice as compared to controls.   Because our 
studies indicated that PIK3IP1 expression in hepatocytes suppressed hepatic PI3K activity as 
well as hepatocyte DNA synthesis in culture, we chose to examine hepatocyte replication in situ 
in the livers of the TG and NTG animals.  Typically, the vast majority of hepatocytes are in a 
state of quiescence (i.e., in G0) in vivo.  For example, Counts et al. (Counts et al., 1996) pulsed 
mice of two different strains (B6C3F1 and C57B/6) with BrdU for one week, sacrificed the 
animals, and determined the hepatocyte BrdU labeling index as a measure of proliferation.  They 
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noted that only 2-4% of hepatocytes labeled with BrdU indicating that a minor proportion of 
normal hepatoyctes were engaged in the cell cycle.  We observed that hepatocyte replication in 
our TG animals was reduced:  the percentage of hepatocytes staining with the proliferation 
marker Ki67 was about two-thirds less in TG mice than that observed in control animals.  Thus, 
one mechanism by which PIK3IP1 suppresses liver tumorigenesis in mice may be through 
inhibition of innate hepatocyte replication, a process that we show is likely to be at least partially 
dependent on PI3K signaling.   
Altogether, our in vivo and in vitro data demonstrating that hepatic PIK3IP1 expression 
negatively regulates PI3K activity in this tissue and suppresses the development of HCC coupled 
with our findings that PIK3IP1 protein expression is reduced in most cases of human HCC point 
to a tumor suppressor-like function for PIK3IP1 and suggest that downregulating PI3K may well 
have an inhibitory effect on liver tumorigenesis, a notion that deserves further attention. 
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4.0  PIK3IP1 ALTERS THE LIVER PHOSPHOPROTEOME IN VIVO AND IN 
VITRO 
4.1 INTRODUCTION 
Given the multiple functions of PIK3IP1 in cell signaling, especially in relationship to 
PI3K, MAPK and Ras, we were prompted to investigate its role on modifying the 
phosphoproteome in the liver. We determined that endogenous hepatic PIK3IP1 expression is 
low in liver tissue, while levels of phospho-Akt (pAkt), a marker of PI3K activity, are 
upregulated. We next wanted to investigate the role of PIK3IP1 on gene and protein expression 
in liver tissues and hepatocytes. To do so, we utilized the PIK3IP1 overexpressing transgenic 
mice discussed in chapter 3. We then interrogated protein expression changes between PIK3IP1 
transgenic (TG) and nontransgenic (NTG) livers and hepatocytes.  
4.2 MATERIALS AND METHODS 
 
4.2.1 Phospho-protein analysis in mouse livers 
Liver tissues were collected from 6 male littermates (3 TGs and 3 NTGs) aged 6 months.  
For each animal, 0.1g of liver tissue was subjected to protein extraction and each group of 
samples were pooled equally. The liver lysates were sent to Kinexus Bioinformatics Corporation 
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(Kinexus) where Kinexus KinetworksTM Biosource Phospho-Site Screening (KPSS-7.0) was 
performed for detection of 38 phosphorylation sites (Figure 20). 
 
 
Figure 20: Flow chart for phospho-protein profiling of liver tissues harvested from 
PIK3IP1 TG and NTG littermates. 
 
4.2.2 Phospho-protein analysis in mouse hepatocytes 
Six male littermates (3 TGs and 3 NTGs), aged 6 months, were selected to collect the 
hepatocytes by liver perfusion.  For each animal, 9 million hepatocytes were seeded in each of 
two 100 mm2 dishes. In total, 6 dishes of hepatocytes from either 3 TGs or 3 NTGs were 
harvested after 12 hrs in culture under serum-free condition. Cell pellets were washed three times 
with PBS and were dissolved in protein lysis buffer. Five hundred microliter of protein lysate 
was taken from each animal and animal samples were pooled, mixed with 2x sample buffer, and 
sent to Kinexus where KinetworksTM Biosource Phospho-Site Screening (KPSS-7.0) was 
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perfomed for hepatcocytes phosphoprotein profiling, which can detect 38 phosphorylation sites 
at the same time (Figure 21 and Table 1). 
 
Figure 21: Flow chart for phospho-protein profiling of hepatocytes isolated from PIK3IP1 
TG and NTG littermates.  
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Table 1. Phospho-protein targets interrogated by KinetworksTM KPSS 7.0 phosphoprotein 
analysis.  
The cognate targets of 38 different phospho-specific antibodies applied in the present study are 
listed. Y = tyrosine S = serine T = threonine 
 
No.  Abbreviation  Full Name of Protein  Epitope(s) 
1 CDK1/2  Cyclin-dependent protein-serine kinase 1/2  T14+Y15 
2 Dok-2  Docking Protein 2 (mouse)  Y142 
3 EGFR  Epidermal growth factor receptor-tyrosine kinase  Y1148 
4 eIF-2 a  Eukaryotic translation initiation factor 2 alpha S51 
5 eIF4G  Eukaryotic translation initiation factor 4 gamma 1  S1107 
6 Erk1  Extracellular regulated protein-serine kinase 1 (p44 MAP kinase) T202+Y204 
7 Erk2  Extracellular regulated protein-serine kinase 2 (p42 MAP kinase) T185+Y187 
8 FAK Focal adhesion protein-tyrosine kinase  Y576 
9 FAK   Focal adhesion protein-tyrosine kinase S722 
10 FAK Focal adhesion protein-tyrosine kinase S843 
11 FAK  Focal adhesion protein-tyrosine kinase Y861 
12 FAK  Focal adhesion protein-tyrosine kinase S910 
13 GSK3 a  Glycogen synthase-serine kinase 3 alpha  Y279 
14 GSK3 b Glycogen synthase-serine kinase 3 beta  Y216 
15 Integrin a4  Integrin, alpha 4 (VLA4)  S988 
16  Integrin b1  Integrin, beta 1 (fibronectin receptor beta subunit, CD29 antigen)  S785 
17 IR  Insulin receptor  Y999 
18 IRS1 Insulin receptor substrate 1  Y612 
19 IRS1  Insulin receptor substrate 1  Y1179 
20 JNK  Jun N-terminus protein-serine kinases  T183+Y185 
21 MAPKAPK2  Mitogen-activated protein kinase-activated protein kinase 2  T334 
22 MEK1  MAPK/ERK protein-serine kinase 1(MKK1)  T291 
23 MEK1 MAPK/ERK protein-serine kinase 1(MKK1)  S297 
24 MEK1  MAPK/ERK protein-serine kinase 1(MKK1)  T385 
25 MEK2  MAPK/ERK protein-serine kinase 2 (MKK2) human T394 
26 MEK2  MAPK/ERK protein-serine kinase 2 (MKK2) mouse  T394 
27 p38 a  MAPK Mitogen-activated protein-serine kinase p38 alpha  T180+Y182 
28 PKBa (Akt1)  Protein-serine kinase B alpha (Akt1)  S473 
29 PRAS40  Proline-rich Akt substrate 40 kDa (Akt1S1)  T246 
30 PTEN  Phosphatidylinositol-3,4,5-trisphosphate3-phosphatase and protein  S380+S382+S385
31 RSK1/2  Ribosomal S6 protein-serine kinase 1/2  S221/S227 
32 RSK1/2  Ribosomal S6 protein-serine kinase 1/2 S363/S369 
33 RSK1/2  Ribosomal S6 protein-serine kinase 1/2  S380/S386 
34 S6Ka  p70 ribosomal protein-serine S6 kinase alpha  T229 
35 Shc1  SH2 domain-containing transforming protein 1  Y349+Y350 
36 Src  Src proto-oncogene-encoded protein-tyrosine kinase  Y418 
37 Src  Src proto-oncogene-encoded protein-tyrosine kinase  Y529 
38 Vinculin  Vinculin  Y821 
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4.2.3 Isolation and culture of primary mouse hepatocytes  
Mouse hepatocytes were isolated from male PIK3IP1 TG and NTG littermates by the in 
situ two-step collagenase perfusion technique as we described in chapter 3 (Bell et al., 1999). 
Hepatocytes were pelleted by centrifugation, assessed for viability by Trypan Dye exclusion 
which typically ranged from 70 – 90%, and cultured in Eagle’s Minimal Essential Medium 
(EMEM—Cellgro, Herndon, VA) containing 10% fetal bovine serum.   
4.2.4 Protein isolation, SDS-PAGE and Western blot analysis 
For Kinexus phospho-protein analysis, liver tissues were homogenized in lysis buffer (20 
mM Tris, 20 mM β-glycerophosphate, 150 mM NaCl, 3 mM EDTA, 3 mM EGTA, 1 mM 
Na3VO4, 0.5% Nonidet P-40, and 1 mM dithiothreitol) supplemented with protease inhibitor 
cocktail (Sigma aldrich, Cat# P8340) and phosphatase inhibitor cocktail 2 (Sigma Aldrich, Cat# 
P5726). For hepatocytes, cells were washed with PBS before scraped in lysis buffer. By 
centrifugation at 100,000 rpm for 30 min at 4 °C, tissue or cell debris was removed. Protein 
concentration was determined by the BCA protein assay. 
 
4.2.5 Extraction of total RNA and Taqman qRT-PCR  
To detect hepatic PIK3IP1 mRNA expression,total RNA was extracted according to the 
TRIzol manufacturer's protocol (Invitrogen, Carlsbad, CA) from TG (n = 8) and NTG (n = 11) 
mouse liver tissue.  Animals ranged in age from 1 – 6 mo. RNA was reverse transcribed by 
standard procedures and then subjected to qRT-PCR analysis for 40 cycles using the ABI Prism 
7000 Sequence Detection System with TaqMan® Gene Expression Assays reagents as well as 
primers specific for mouse PIK3IP1 purchased from Applied Biosystems (Foster City, CA, 
Assay ID: Mm01191492_m1).  18S rRNA primer (Applied Biosystems, Assay ID: 
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HS99999901_S1) was used as an internal control for sample quality, and DEPC water was used 
as a negative control for product contamination. 
 
4.2.6 PIK3IP1 abundance and PI3K activity among different mouse tissues  
Two C3H wild type mice aged 6 months were sacrificed and the spleen, liver, lung, 
kidney and heart tissues were collected for protein extraction and total RNA extraction. 
For comparison of PI3K activity among different tissues, protein was isolated by RIPA 
buffer and Western blot was performed against phosphor-Akt antibody and total Akt antibody 
(as described in Chapter 2.2.5.) Phospho-Akt level in each tissue was first normalized by total 
Akt level and then was converted to relative fold of that in the heart tissue. 
For comparison of PIK3IP1 abundance among different tissues, total RNA was extracted 
and Taqman qRT-PCR was carried out to detect the endogenous PIK3IP1 mRNA levels in these 
tissues..  
 
4.2.7 Kinexus protein kinase profiling assay 
The protein lysates were sent to Kinexus for the KinetworksTM phosphor-protein profiling 
assay, which was performed according to the handbook of KinetworksTM. Briefly, 300 μg of total 
protein were loaded on a 13% single lane SDS-polyacrylamide gel (SDS-PAGE). Proteins were 
transfer from SDS-PAGE to nitrocellulose membrane and the latter was incubated with different 
mixtures of antibodies with distinct molecular masses. After further incubation with secondary 
antibodies (Santa Cruz Biotechnology), the blots were developed using ECL Plus reagent 
(Amersham Biosciences), and signals were quantified using Quantity One software (Bio-Rad). 
The panel of target phosphoproteins detected by the Kinetworks™ KPSS 7.0 screen is listed in 
Table 1. Detailed information and protocols of the Kinetworks™ analysis have been reported 
(Pelech et al., 2003) and can also be found at the Kinexus website (www.kinexus.ca) 
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 4.2.8 Statistics and data analysis 
For the Taqman qRT-PCR data, a 2-∆∆Ct method was adopted to compare the relative fold 
change between TG and NTG PIK3IP1 mRNA expression levels (Livak et al., 2001). PIK3IP1 
expression level was normalized to 18S rRNA expression by calculating ∆Ct (Average 
PIK3IP1Ct-Average18SCt). Next, we compared normalized PIK3IP1 expression between TGs 
and NTGs, adjusting the PIK3IP1 expression value by calculating ∆∆Ct (Average ∆CtTG-
Average∆CtNTG). Then to obtain the relative fold, 2-∆∆Ct was calculated, and 2-∆∆Ct is the 
normalized PIK3IP1 amount relative to NTGs (relative fold). Student’s t-test was used for the 
comparison of relative fold, and p<0.05 was considered statistically significant. 
For the PIK3IP1 abundance among different tissues, relative abundance of PIK3IP1 
mRNA from each tissue was normalized according to that in the heart. Then Pearson correlation 
coefficient was used to predict the possible correlation between pAkt levels and PIK3IP1 levels 
in different tissues.  
 
4.3 RESULTS 
4.3.1 Endogenous PIK3IP1 abundance is negatively correlated with PI3K activity 
among different tissues 
We examined PIK3IP1 mRNA expression and pAkt protein levels in 5 normal tissues 
including heart, spleen, lung, kidney and liver isolated from two wild type male C3H mice. Each 
tissue harvested from two animals was pooled and homogenized for protein extraction. We 
performed western blots for pAkt (normalized by total Akt) and qRT-PCR for PIK3IP1 mRNA 
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(normalized by 18S ribosome RNA). Relative fold expression was normalized to that of heart 
tissue. We observed that tissues with the lowest PIK3IP1 mRNA expression, such as the liver 
and kidney, have the highest pAkt level, whereas heart tissue with the highest PIK3IP1 mRNA 
expression has the lowest pAkt level. After a correlation study, we found a negative correlation 
(Pearson’s r= -0.92813) between the Akt phosphorylation level and PIK3IP1 mRNA level 
among the tissues (Figure 22). This suggests that high amount of PIK3IP1 may contribute to low 
PI3K activity in tissues.  
 
 
Figure 22:  PIK3IP1 abundance is negatively correlated with PI3K activity in 
different tissues.  
Normalized pAkt and PIK3IP1 mRNA levels from different tissues were compared, relative fold to heart 
was determined, and a correlation study was performed. 
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4.3.2 Time-course expression of PIK3IP1 mRNA in liver tissues 
As shown in Figure 23, in the NTGs, PIK3IP1 mRNA expression remained stable at a 
low level following birth. However, for TGs, the high hepatic PIK3IP1 mRNA expression was 
noted as early as 1 month and remained elevated at 16 months. (*=p<0.01) 
 
 
 
Figure 23: PIK3IP1 mRNA is overexpressed in PIK3IP1 TG mouse livers.  
Time-course comparison of hepatic PIK3IP1 mRNA levels between TG and NTG 
littermates. Mice littermates aged from 0.5 to 16 months were sacrificed and the liver tissues 
were harvested for mRNA extraction. Two to three animals in each group were compared for the 
relative fold of PIK3IP1 mRNA abundance.  
 
4.3.3 Comparison of protein phosphorylation between TG and NTG mouse livers  
Because PI3K/Akt pathway is involved in protein phosphorylation, and because PIK3IP 
negatively regulates PI3K, we suspected that PIK3IP overexpression would change the protein 
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phosphorylation pattern in hepatocytes and liver tissue. Therefore, we used the Kinexus 
phospho-antibody screening system to compare the protein phosphorylation profile of TG and 
NTG livers. This is an efficient tool for discovery and definition of kinase signaling pathways 
(Sayed et al., 2000). The KinetworksTM KPSS 7.0 array interrogates 38 protein phosphorylation 
sites involved in cell proliferation at the same time (Table 1).  
We found that phosphorylation of RSK1/2 [S363/S369], GSK3 beta [Y216], Src [Y529], 
MEK1[S297], Erk2 [T185/T187 ], FAK [S910] and Akt [S473] were reduced in TG mouse livers 
as compared to controls. At the same time, we observed that phosphorylation of Dok2 [Y142], 
eIF2a [S51], PTEN [S380+T382+S385] and IR [Y999] were increased in TG mouse livers 
(Table 2 and Figure 24). Most of these proteins are downstream targets of the PI3K (Figure 3). 
Therefore, these results are consistent with our previous findings that PIK3IP1 suppresses the 
PI3K signaling pathway. 
 
 
 
Figure 24: PIK3IP1 overexpression in the liver changes its phospho-protein profile.  
Changes in the intensity of phosphorylation signals are evident in PIK3IP1 TG liver tissues (Left) as 
compared with NTG liver tissues (Right) 
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Table 2: Phospho-protein changes in PIK3IP1 TG liver tissues as compared to NTG 
controls 
 
protein name epitope Tg:NTG Expected outcome 
RSK1/2 [S380/S386] -65% transcriptional regulation 
GSK3-beta [Y216] -42% ↓Beta catenin; ↓Proliferation 
Src [Y529] -37% ↓cell adhesion, migration, and cancer progression 
MEK1 [S297] -36% ↓proliferation & differentiation 
Erk2 [T185/T187 ] -29% ↓survival & growth 
Focal adhesion protein-
tyrosine kinase (FAK) [S910] -27% 
↓cell spreading, differentiation, 
migration & survival 
Proline-rich Akt substrate 
40 kDa (Akt1S1, PRAS40) T246 -26% ↓mTOR1 activity 
GSK3-alpha Y279 -25% ↓β-catenin activity 
Akt [S473] -13% ↓PI3K signaling 
Dok2 [Y142] 11% 
negatively regulate signal 
transduction and cell proliferation 
controlled by cytokines in a 
feedback loop 
Eukaryotic translation 
initiation 
factor 2 alpha (eIF2a) 
[S51] 23% Regulation of protein synthesis 
PTEN [S380+T382+S385] 35% ↑PTEN protein stability (Torres et al., 2001) 
Insulin receptor (IR) [Y999] 54% ↑IR signaling (compensatory?)  
 
4.3.4 Comparison of protein phosphorylation between TG and NTG mouse 
hepatocytes  
Similar to the changes observed in vivo, we found that phosphorylation of RSK1/2 
[S221/S227], PRAS40 [T246], Erk1 [T202+Y204], Akt1 [S473], p38 MAPK [T180+Y182] and 
IRS1 [Y612] were reduced in TG mouse hepatocytes as well. At the same time, we observed that 
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phosphorylation of eIF2a [S51], PTEN [S380+T382+S385] and IR [Y999] were increased in TG 
mouse hepatocytes (Table 3).  
 
Table 3: Phospho-protein changes in PIK3IP1 TG hepatocytes as compared to NTG hepatocytes  
protein name epitope TG:NTG Expected outcome 
RSK1/2 S221/S227 -66% transcriptional regulation 
Proline-rich Akt substrate 40 
kDa (Akt1S1, PRAS40) T246 -45% ↓PI3K signaling 
Erk1 T202+Y204 -39% ↓survival & growth 
PKB/Akt1 S473 -36% ↓PI3K signaling 
P38 MAPK T180+Y182 -33% ↓cell differentiation & growth 
IRS1 Y612 -28% ↓PI3K recruitment (Esposito et al., 2001) 
p70 ribosomal protein-serine 
S6 kinase alpha (p70S6K) T229 52% ↓cell cycle & cell growth 
Dok2 Y142 60% 
negatively regulate signal 
transduction and cell 
proliferation controlled by 
cytokines in a feedback loop 
Src Y418 83% Src activation 
Jun N-terminus protein-serine 
kinase (stress-activated 
protein kinase (SAPK); 
(JNK1+JNK2) 
T183/Y185 100% JNK pathway 
Eukaryotic translation 
initiation factor 2 alpha 
(eIF2a) 
S51 119% Regulation of protein synthesis
 
 
4.4 DISCUSSION 
In the present study, we demonstrated that endogenous PIK3IP1 expression is negatively 
correlated with tissue PI3K activity. This is a very interesting phenomenon, because it suggests 
that PIK3IP1, a negative PI3K regulator, may be a determinant factor of tissue PI3K activity. 
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This can be explained by the fact that PIK3IP1 directly binds with p110 catalytic subunit of PI3K 
and suppress its activity.  
We also demonstrated that overexpression of PIK3IP1 in hepatocytes dramatically 
changes protein phosphorylation both in vivo and in vitro. Noticeably, many kinases that we 
examined in this study showed decreased phosphorylation in PIK3IP1 TG liver tissues and 
hepatocytes, suggesting that PIK3IP1 widely suppresses proliferation and survival through these 
patheays. Interestingly, most of the proteins demonstrating changes in phosphorylation by 
PIK3IP1 overexpression are direct or indirect targets of the PI3K pathway (such as Akt, GSK3, 
PRAS40, Erk1 and JNK1/2).  
In conclusion, we confirmed that PIK3IP1 mRNA abundance is negatively correlated 
with PI3K activity in the mural tissues. Furthermore, hepatic PIK3IP1 overexpression altered the 
hepatic phospho-proteome both in vivo and in vitro, probably through suppression of PI3K/Akt 
pathway. These observations help to explain PIK3IP1’s activity to dampen proliferation and 
survival, and provide further evidence as to how PIK3IP1 reduces HCC tumorigenesis we 
observed in PIK3IP1 TG mice.   
 
 
 
 
 50 
5.0  PIK3IP1 OVEREXPRESSION INDUCES HYPERGLYCEMIA AND OBESITY 
5.1 INTRODUCTION 
Insulin signaling is a critical component in the maintenance of whole-body glucose and 
fat homeostasis. Insulin activates the membrane receptor which in turn activates insulin receptor 
substrate-1 (IRS-1) by phosphorylation (Dresner et al 1999; Yu et al 2002). The liver plays a key 
role in insulin induced glucose metabolism in two ways: 1). By controling glucose uptake 
through glycogenesis; and 2) by releasing glucose via glycogenolysis and gluconeogenesis. 
Insulin stimulates glycogen synthesis by activating glycogen synthase (GS) through 
dephosphorylation. Akt-mediated inactivation of GSK-3 contributes to a reduction in the net 
phosphorylation of GS and a further induction of glycogen synthesis (Whiteman et al., 2002). 
Therefore, gain-of-function in PI3K leads to hypoglycemia, which is the main manifestation in 
PTEN knockout mice and mice harboring activated Akt (Stiles B, 2007 and Ono H, et al., 2003).  
The PI3K pathway is also involved in liver adipogenesis. Activation of Akt induces 
synthesis of SREBP-1 and SREBP-2, which will lead to the induction of key enzymes of the 
cholesterol and fatty acid biosynthesis pathways, such as fatty acid synthase. Therefore, 
activation of PI3K/Akt induces an increase in the concentration of liver triglyceride (Porstmann 
et al. 2005; Ono H et al., 2003).  
Although hepatocyte-specific Pten knock-out mice and mice overexpressing Akt display 
steatohepatitis (Horie Y et al., 2004), hepatic overexpression of HGF dramatically ameliorates a 
high-fat diet-induced fatty liver (Kosone T, et al., 2007). HGF/Met can activate another 
important factor of energy metabolism, the Ras/Raf/MEK/ERK kinase cascade. Erk1-MAPK 
mediated phosphorylation of PPARγ associated with adipogenesis in fat cells (Hu E, et al. 1996). 
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Since both PI3K and Ras/MAPK activities are impaired in PIK3IP1 transgenic hepatocytes, we 
hypothesize that our PIK3IP1 TG mice may have disturbed glucose and triglyceride metabolism. 
5.2 MATERIALS AND METHODS 
5.2.1 Animals 
PIK3IP1 TG and NTG male littermates aged 8-10 months old were used for the 
experiments. For metabolic measurements, animals were fasted overnight. Blood samples were 
then taken for assessment of glucose and triglycerides by using manufactured kits. For tissue 
collection, mice were fasted overnight and blood was collected from cardiac puncture after the 
measurement of the body weight. And then, the visceral fat was taken out from the abdomen and 
weighted. Liver tissues were flash-frozen in liquid nitrogen for protein analysis or liver 
triglyceride analysis.  
5.2.2  Western blot analysis 
Protein sample preparation and SDS/PAGE were performed as mentioned in chapter 
2.2.5. Blots were probed with phospho-insulin receptor β (Tyr1146) Antibody (Cell Signaling 
Technology, Inc., Cat#: 3021) and the same blots were reprobed with insulin receptor β antibody 
(Santa Cruz Biotechnology Inc., Cat#: SC-711). 
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5.2.3 Statistical analysis 
Statistical analysis was carried out using a two-tailed Student’s t-Test unless otherwise 
specified. Results were considered to be statistically significant when p values were determined 
to be less than 0.05.   
.  
5.3 RESULTS 
5.3.1 Mice overexpressing PIK3IP1 in hepatocytes display increased body weight 
and visceral fat deposition 
To identify the possible role of PIK3IP1 in metabolism, we performed a cohort study. 
Five TG and five NTG male littermates, aged 8-10 months, were assessed for body weight and 
visceral fat weight. As a result of PIK3IP1 overexpression in the liver, we found a 3-fold 
increase of visceral fat deposition in TG males (Figures 25 B&C). We also observed a significant 
increase of the body weight in our PIK3IP1 TG mice (Figure 25A, open bar). Taken together, 
these results suggest that PIK3IP1 overexpression in the liver is associated with deregulation of 
fat metabolism and can lead to visceral obesity. 
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Figure 25: Mice overexpressing PIK3IP1 in hepatocytes display increased body 
weight and visceral fat deposition. 
 (A) TG mice have increased body weight. *p=0.016; and (B)increased visceral fat. **p=0.0003. (C) 
Images depicting visceral fat from PIK3IP1 NTG (Left) and TG (Right) mice. 
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 5.3.2 Serum fasting glucose is elevated in mice with hepatic overexpressing of 
PIK3IP1 
Because both the body weight and the visceral fat weight are related to insulin resistance, 
we then evaluated serum fasting glucose between TG and NTG littermates from the same cohort. 
PIK3IP1 overexpression was associated with an increase in fasting serum glucose levels in the 
TGs (Figure 26). This suggests that PIK3IP1 may contribute to insulin resistance. 
 
Figure 26: Fasting serum glucose levels are elevated in PIK3IP1 TG mice (open bar).  
5.3.3 PIK3IP1 overexpression increased insulin receptor (IR) phosphorylation 
Because IR is the key receptor responsive for insulin signaling, we compared the 
phosphorylation pattern of IR between TG and NTG livers. In TGs, IR phosphorylation was 
significantly higher than that in NTGs (Figure 27).  
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 Figure 27: PIK3IP1 overexpression increased phosphorylation of insulin receptor.   
A Western blotting analysis showed that IR phosphorylation is increased in Tg livers. 
 
5.4 DISCUSSION 
 
IR and IRS proteins activate PI3K which leads to Akt stimulation. This IR-IRS-PI3K-
Akt axis is known to play a critical role in insulin-induced metabolism (Saltiel AR et al., 2001; 
Whiteman E et al., 2002; Miyake K et al., 2002) and the homeostasis of which will be altered if 
the components are modulated or disrupted. 
Overexpression of PIK3IP1 in the liver resulted in hyperglycemia and obesity. These 
indices are strong determinants for diabetes and insulin resistance. PIK3IP1 suppresses PI3K 
activity, which may inhibit the transport of the blood glucose into the liver. One downstream 
protein of PI3K/Akt pathway is GSK-3. Insulin-stimulated protein kinase B (PKB/Akt) and 
GSK-3beta phosphorylation, therefore reduce hepatic glucose output and induce hepatic 
glycogen synthesis.  GSK-3 activity is elevated in human and rodent models of diabetes, and 
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various GSK-3 inhibitors improve glucose tolerance and insulin sensitivity in rodent models of 
obesity and diabetes. As shown in our phospho-protein array study, PIK3IP1 overexpression 
inhibit Akt induced GSK-3 phosphorylation (Table 2) and IRS phosphorylation (Table 3). 
Therefore, PIK3IP1 likely increases blood glucose by inhibiting the PI3K/GSK-3 pathway. 
Surprisingly, the abundance of tyrosine phosphorylated IR was upregulated in TGs. We 
confirmed this observation by WB. This finding is likely explained by the fact that hepatic 
signaling downstream of IR at the level PI3K is dampened by PIK3IP1 in the TGs.  Thus, it is 
possible that IR hyperphosphorylation reflects a compensatory mechanism in TGs to overcome 
resistance at the level of PI3K.  It would thus follow that PIK3IP1 TGs are hyperinsulinemic. 
This possibility is one that we will explore in the specific aims of our application.  
In conclusion, in the present study, we demonstrated that overexpression of PIK3IP1 in 
the liver dramatically increased visceral fat, liver fat, and serum fasting glucose. Further studies 
are needed to elucidate whether this defect is caused by the suppressive effect of PIK3IP1 on 
IR/PI3K pathway and/or HGF/Met/Erk pathway.      
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6.0  DISCUSSION 
6.1 SUMMARY 
The objective of this dissertation was to elucidate the role of PIK3IP1, a negative PI3K 
regulator, in hepatic tumorigenesis and metabolism. We successfully generated a transgenic 
mouse model with hepatic overexpression of PIK3IP1 level as early as one month after birth. 
The high PIK3IP1 level in the liver significantly suppressed PI3K pathways as shown by 
KinexusTM phospho-protein assay and PI3-kinase assay. 
Previously, we showed through a variety of in vitro experiments that PIK3IP1 binds to 
the p110 catalytic subunit of PI3K through PIK3IP1’s intracellular p85-like domain to 
downregulate PI3K activity (Zhu et al., 2007).   However, we had not elucidated the role of 
PIK3IP1 in controlling PI3K activity in vivo. This study represents the first time that hepatic 
overexpression of PIK3IP1 can suppress tumorigenesis of hepatocellular carcinoma, mainly 
through curbing PI3K pathway.  
In addition, hepatic overexpression of PIK3IP1 leads to hyperglycemia and high visceral 
fat deposition. This indicates that PIK3IP1 may contribute to insulin resistance, and the higher 
order implications of the findings are the focus of future studies.
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 6.2 FUTURE DIRECTIONS 
Based on the current results, there are several directions which are critical for us to 
investigate. First, we want to know how the effect of PIK3IP1 loss-of-function to liver 
homeostasis. Since PIK3IP1 is a negative regulator of PI3K, loss of PIK3IP1 should increase 
PI3K activity. This could result in upregulated replication and survival of hepatocytes and could 
induce HCC tumorigenesis. Furthermore, once PIK3IP1 is knocked out, elevated PI3K activity 
in the liver may also change glucose and triglyceride metabolism. This will probably induce 
hypoglycemia, since insulin signaling through PI3K may be enforced when PIK3IP1 expression 
is switched off in the liver. 
The second direction we would like to follow is the role of PIK3IP1 in liver regeneration. 
The Akt/PKB pathway has been shown to be activated during liver regeneration and pancreatic 
regeneration. Phospho-Akt levels increased as early as 30 min. after two thirds partial 
hepatectomy (PHx) in mice, suggesting a possible mechanism of PI3K in liver regeneration 
(Hong et al., 2000). However, the role of PI3K in liver regeneration still remains unclear. A 
recent paper by Jackson et al. shows that wortmannin administration in mice dampens liver 
regeneration following 2/3 Phx at the second day time point. The effect of siRNA treatment to 
knock down p85 alpha or p110 alpha is slightly more dramatic resulting in a more pronounced 
inhibition of liver regeneration. Hepatic resection is associated with rapid proliferation and 
regeneration of the remnant liver lobes. Many growth factors and cytokines, most notably 
hepatocyte growth factor, epidermal growth factor, transforming growth factor-alpha, 
interleukin-6, tumor necrosis factor-alpha, insulin, and norepinephrine, appear to play important 
roles in this process. Therefore, PIK3IP1 may be involved in liver regeneration as a negative 
regulator. Our future study will focus on: i) defining the involvement of the PI3K/Akt pathway in 
hepatic regeneration, and ii) determining the effects of PI3K inhibition by PIK3IP1 on hepatic 
regeneration following partial hepatectomy.  
.  
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